NCT01614886 - Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) | Biotech Hunter

Enrollment

216

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Alzheimer's Disease

Interventions

DRUG

Active Comparator

1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.

DRUG

ENA713

-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.

Trial Locations (50)

446-8510

Novartis Investigative Site, Anjo

474-8511

Novartis Investigative Site, Ōbu

489-8642

Novartis Investigative Site, Seto

470-1168

Novartis Investigative Site, Toyoake

010-0874

Novartis Investigative Site, Akita

260-8712

Novartis Investigative Site, Chiba

791-0295

Novartis Investigative Site, Tōon

814-0180

Novartis Investigative Site, Fukuoka

375-0017

Novartis Investigative Site, Fujioka

734-8530

Novartis Investigative Site, Hiroshima

728-0013

Novartis Investigative Site, Miyoshi

309-1793

Novartis Investigative Site, Kasama

247-8533

Novartis Investigative Site, Kamakura

212-0016

Novartis Investigative Site, Kawasaki

216-8511

Novartis Investigative Site, Kawasaki

252-5188

Novartis Investigative Site, Sagamihara

241-0811

Novartis Investigative Site, Yokohama

780-0842

Novartis Investigative Site, Kochi

780-8037

Novartis Investigative Site, Kochi

861-1116

Novartis Investigative Site, Kōshi

860-8556

Novartis Investigative Site, Kumamoto

861-8002

Novartis Investigative Site, Kumamoto

600-8558

Novartis Investigative Site, Kyoto

607-8411

Novartis Investigative Site, Kyoto

616-8255

Novartis Investigative Site, Kyoto

982-8523

Novartis Investigative Site, Sendai

889-1911

Novartis Investigative Site, Kitamorokata-gun

399-8204

Novartis Investigative Site, Azumino

399-8701

Novartis Investigative Site, Matsumoto

940-2302

Novartis Investigative Site, Nagaoka

710-0826

Novartis Investigative Site, Kurashiki

700-8607

Novartis Investigative Site, Okayama

590-0018

Novartis Investigative Site, Sakai

565-0871

Novartis Investigative Site, Suita

565-0874

Novartis Investigative Site, Suita

842-0192

Novartis Investigative Site, Kanzaki-gun

344-0036

Novartis Investigative Site, Kasukabe

333-0832

Novartis Investigative Site, Kawaguchi

343-0032

Novartis Investigative Site, Koshigaya

338-0003

Novartis Investigative Site, Saitama

420-8688

Novartis Investigative Site, Shizuoka

424-8636

Novartis Investigative Site, Shizuoka

770-8503

Novartis Investigative Site, Tokushima

113-8603

Novartis Investigative Site, Bunkyo-ku

193-0998

Novartis Investigative Site, Hachiōji

136-0075

Novartis Investigative Site, Koto-ku

180-8610

Novartis Investigative Site, Musashino

143-0016

Novartis Investigative Site, Ōta-ku

190-8531

Novartis Investigative Site, Tachikawa

752-8510

Novartis Investigative Site, Shimonoseki